Zacks Small Cap Research on MSN
EDSA: Preparing for mid-2026 start to phase 2 vitiligo trial
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Vitiligo Trial to Initiate in Mid-2026 Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of EB06, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results